Petri

Petri is a Boston-based biotech-focused accelerator and venture vehicle launched by Pillar VC and Ginkgo Bioworks, designed to back hard-tech, life-sciences and bioengineering startups at the earliest stages. The program traditionally pairs initial capital, typically in the $250K range, with deep operational support including lab space, scientific advising and access to Ginkgo’s foundry capabilities. Focus areas span synthetic biology, novel therapeutics, biomanufacturing, agricultural biotech, food and adjacent life-sciences applications, with a strong bias toward technical founders building from scientific breakthroughs. For healthcare founders, Petri is highly relevant if you are a scientific founder building from a life-sciences or bioengineering insight at the formation stage, particularly if you would benefit from structured access to lab infrastructure and bioengineering tooling. The firm is a poor fit for digital health, healthcare services, healthcare IT, AI-only software and commercial-stage healthcare companies; the program is explicitly oriented toward science-driven biotechs at company inception. Founders best suited typically have a PhD-level technical foundation, a defensible scientific approach, and a willingness to relocate or commit time to the Boston-area ecosystem. Entry is via the program’s open application process, supplemented by warm introductions from scientific advisors, Pillar and Ginkgo network connections, and faculty in target research labs. Founders should expect rigorous scientific diligence and a multi-year commitment to a structured program path with follow-on financing typically led by life-sciences specialists in subsequent rounds.